Regeneron Acquires UK-Based Biotech Oxular

Regeneron, a global biotechnology leader, has acquired Oxular, a UK-based clinical-stage company specializing in ocular delivery technology for retinal disorders. While the financial terms of the acquisition have not been disclosed, the development marks a significant step in Regeneron’s commitment to advancing ophthalmology treatments.

Details of the Acquisition

Neither Regeneron nor Oxular has released a formal statement about the acquisition. However, Mark Gaffney shared his thoughts on LinkedIn, stating:

"The ophthalmology team at Regeneron is uniquely positioned to maximize the use of Oxular’s proprietary technologies. A special thank you to all of the employees, advisors, Board members and shareholders who made this transaction possible. I wish each of you all the best in your next ventures."

Notably, Mr. Gaffney, who recently assumed the role of CEO at Calluna Pharma, expressed optimism about the potential impact of this acquisition.

Oxular's Lead Candidate: OXU-001

Oxular's leading drug candidate, OXU-001, targets diabetic macular edema (DME), a major retinal disorder. Key features of OXU-001 include:

       • Active Ingredient: OXU-001 is a dexamethasone formulation utilizing Oxuspheres, a novel biodegradable drug preparation.

       • Targeted Delivery: It is optimized for delivery to the posterior suprachoroidal space of the eye using Oxulumis, Oxular’s proprietary illuminated microcatheter.

       • Advantages: This in-office treatment provides precise delivery to areas of high disease activity, potentially resulting in:

               - Enhanced efficacy

               - Favorable tolerability

               - Extended durability of up to one year

Clinical Trials for OXU-001

In October 2023, Oxular achieved a significant milestone by dosing the first patient in the OXEYE trial. This randomized, two-part phase 2 trial is designed to evaluate the safety and efficacy of a single suprachoroidal administration of OXU-001 over 52 weeks in patients with DME.

Conclusion

This acquisition positions Regeneron to leverage Oxular’s advanced ocular delivery technology, potentially transforming treatment options for retinal disorders like DME. The addition of OXU-001 to Regeneron’s portfolio could bring innovative solutions to patients, enhancing treatment outcomes and quality of care in ophthalmology.